Please login to the form below

Not currently logged in

Checkmate Pharmaceuticals

This page shows the latest Checkmate Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Regeneron set to acquire Checkmate for approximately $250m

Regeneron set to acquire Checkmate for approximately $250m

The deal is expected to be finalised in mid-2022. Regeneron has announced that it will acquire Checkmate Pharmaceuticals in a proposed deal of around $250m. ... We look forward to welcoming the Checkmate team and their complementary scientific acumen to

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Immuno-oncology combinations in lung cancer. Not disclosed. Peregrine Pharmaceuticals. Combination clinical trials. ... Exclusive commercial licence. 165. Cytos Biotechnology. Checkmate Pharmaceuticals. CYT 003 and VLP [virus like particle] platform in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...